341 related articles for article (PubMed ID: 10170453)
1. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
Einarson TR; Addis A; Iskedjian M
Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
[TBL] [Abstract][Full Text] [Related]
2. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
3. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.
Einarson TR; Arikian SR; Casciano J; Doyle JJ
Clin Ther; 1999 Feb; 21(2):296-308. PubMed ID: 10211533
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatments in panic disorder in adults: a network meta-analysis.
Guaiana G; Meader N; Barbui C; Davies SJ; Furukawa TA; Imai H; Dias S; Caldwell DM; Koesters M; Tajika A; Bighelli I; Pompoli A; Cipriani A; Dawson S; Robertson L
Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012729. PubMed ID: 38014714
[TBL] [Abstract][Full Text] [Related]
5. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.
van Baardewijk M; Vis PM; Einarson TR
Curr Med Res Opin; 2005 Aug; 21(8):1271-9. PubMed ID: 16083537
[TBL] [Abstract][Full Text] [Related]
7. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
[TBL] [Abstract][Full Text] [Related]
8. The pharmacoeconomics of venlafaxine in depression.
Morrow TJ
Am J Manag Care; 2001 Sep; 7(11 Suppl):S386-92. PubMed ID: 11570029
[TBL] [Abstract][Full Text] [Related]
9. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
Machado M; Iskedjian M; Ruiz IA; Einarson TR
Pharmacoeconomics; 2007; 25(11):979-90. PubMed ID: 17960955
[TBL] [Abstract][Full Text] [Related]
10. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
Khandker RK; Kruzikas DT; McLaughlin TP
J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness of venlafaxine for the treatment of depression and anxiety. Bibliographic review].
Baca Baldomero E; Rubio-Terrés C
Actas Esp Psiquiatr; 2006; 34(3):193-201. PubMed ID: 16736393
[TBL] [Abstract][Full Text] [Related]
12. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
Sullivan PW; Valuck R; Saseen J; MacFall HM
CNS Drugs; 2004; 18(13):911-32. PubMed ID: 15521793
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.
Freeman H; Arikian S; Lenox-Smith A
Pharmacoeconomics; 2000 Aug; 18(2):143-8. PubMed ID: 11067648
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
Benedict A; Arellano J; De Cock E; Baird J
J Affect Disord; 2010 Jan; 120(1-3):94-104. PubMed ID: 19497623
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden.
Nordström G; Despiegel N; Marteau F; Danchenko N; Maman K
J Med Econ; 2010; 13(3):516-26. PubMed ID: 20698748
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.
Llorca PM; Fernandez JL
Int J Clin Pract; 2007 Apr; 61(4):702-10. PubMed ID: 17394446
[TBL] [Abstract][Full Text] [Related]
17. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.
Lenox-Smith A; Greenstreet L; Burslem K; Knight C
Clin Drug Investig; 2009; 29(3):173-84. PubMed ID: 19243210
[TBL] [Abstract][Full Text] [Related]
19. A pharmacoeconomic evaluation of major depressive disorder (Italy).
Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
[TBL] [Abstract][Full Text] [Related]
20. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder.
Trivedi MH; Wan GJ; Mallick R; Chen J; Casciano R; Geissler EC; Panish JM
J Clin Psychopharmacol; 2004 Oct; 24(5):497-506. PubMed ID: 15349005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
